Blood test could eradicate invasive tumour biopsies
The need for tumour biopsies could be eliminated by 2035 with a simple blood test to detect cancer developed by Manchester start-up Chromition.
With support from the Centre of Expertise in Advanced Materials and Sustainability (CEAMS) and funding from Innovate UK, Chromition’s Luminspheres are highly sensitive fluorescent nanoparticles designed to detect multiple cancer biomarkers on a single cell in a blood sample.
This approach is claimed to allow for earlier, more precise detection, offering clinicians a detailed profile of each patient’s cancer and enabling more personalised treatment plans.
Unlike traditional methods, which often rely on invasive tumour biopsies, Luminspheres provide a non-invasive, faster alternative, with the potential to be incorporated into routine blood tests for early cancer screening.
With approximately 350,000 new cancer cases diagnosed each year in the UK, early detection is critical to improving survival rates. An automated scanner can digitally image one sample every 30 minutes, operating 24/7, thereby increasing capacity and speeding up diagnosis to help meet growing demand.
Register now to continue reading
Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.
Benefits of registering
-
In-depth insights and coverage of key emerging trends
-
Unrestricted access to special reports throughout the year
-
Daily technology news delivered straight to your inbox
Experts speculate over cause of Iberian power outages
The EU and UK will be moving towards using Grid Forming inverters with Energy Storage that has an inherent ability to act as a source of Infinite...